Imugene Rebounds On Receiving Tax Rebate And Advancement To Phase 2 In Gastric Cancer Trial

  • Nov 14, 2018 AEDT
  • Team Kalkine
Imugene Rebounds On Receiving Tax Rebate And Advancement To Phase 2 In Gastric Cancer Trial

Imugene Limited (ASX: IMU), the immuno-oncology company, with its unique technological platform basically tries to harness the immune system of the cancer patients and helps in the generation of the antibodies that can fight against tumors and completely eradicate them from the body. The effects from the IMU technological platform are more or less in line with the effects from the synthetically manufactured monoclonal antibody therapies. IMU product profile contains multiple immunotherapy B-cell vaccine which are used for the treatment of a variety of cancers. The B-cell vaccines are used together with the standard of care drugs and varied emerging immunotherapies for the treatment. IMU is well supported by various international cancer experts having extensive experience in the development of new cancer therapies.

On November 09, 2018, IMU has received a tax rebate of $1.85 million as research and development tax. This tax rebate is basically a part of the Australian government R&D tax incentive. Under this incentive, the important activities in relation to the immuno-oncology research undertaken by Imugene were taken into consideration for the financial year ended on June 30, 2018.

In addition to the funding amount, the receipt of tax rebate of $1.85 m will support IMU’s commercial and clinical activities and set milestone period for the company. September 2018 quarter remained the most significant period in relation to the expenditure made on research and development activities for an amount of approximately $1.65 m.

Tax rebate under Australian government (R&D tax incentive) has been a very encouraging factor for the companies that can engage in conducting more and more new programs in the direction of research and development and get approximately refundable tax offset of 43.5% for all eligible activities.

On November 13, IMU has made the announcement for its progress towards Phase 2 study in Gastric Cancer Immuno-oncology trial. Preparations for the Phase 2 study of HER-Vaxx cancer vaccine in gastric cancer patients will begin in early 2019 after the completion of the Phase 1b study. Activities pertaining to Phase2 preparation have already started.

HER-Vaxx is basically designed to generate an antibody inside the body which can respond against a cancer growth signal receptor protein called HER2 and is commonly found on the surface of the cell-in breast and gastric cancers. Phase1b dose escalating trial completion and the advancement to phase2 study are key milestones to achieve for Imugene. The completion of phase 1 and advancement to phase 2 will definitely be one of the success for many medical professionals who are seeking treatments for patients with advanced gastric cancer and who have very limited set of medical options.

IMU expects to report top-line results before the end of the year and start the random trial for the Phase2 in early 2019. IMU is trading at the levels of $0.022, up 4.7% on November 14, 2018 (3:30 PM AEST).


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

 

 

All pictures are copyright to their respective owner(s).Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.

 

There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

CLICK HERE FOR YOUR FREE REPORT!
   
x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK